Preclinical and clinical evaluation of recombinant human macrophage colony-stimulating factor (rhM-CSF)

Publisher Website
Google Scholar
Abstract
The promise of hematopoietic growth factors is now being realized as clinical trials become more mature. The uses of granulocyte‐macrophage colony‐stimulating factor and granulocyte colony‐stimulating factor are now becoming more established in therapeutic applications of disease states. A variety of new hematopoietic growth factors is on the horizon, including recombinant human macrophage colony‐stimulating factor (rhM‐CSF), which has recently entered clinical trials after extensive preclinical testing. The diverse biological actions of rhM‐CSF will provide novel ways of approaching various medical problems across the disciplines of hematology, oncology, infectious disease and cardiology.